Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-29T07:22:13.644Z Has data issue: false hasContentIssue false
  • English
  • Français

PW01-42 - Escitalopram In Treatment of Disability In Major Depressive Patients

Published online by Cambridge University Press:  17 April 2020

N. Zivkovic ,
D. Pavicevic  and
G. Djokic
N. Zivkovic
Affiliation:
Urgent Psychiatry, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
D. Pavicevic
Affiliation:
Department M, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
G. Djokic
Affiliation:
Consultative Neurology, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Major depressive disorder (MDD) is a common, and often severe affective disorder which causes significant psychological distress, reduces quality of life and incised suicidal risk and mortality. Neurobiological basis of MDD involves at first serotoninergic and noradrenergic neuronal systems. Escitalopram is highly potent and highly selective serotonin re-uptake inhibitor.

Purpose of this study was to

Estimate efficacy of the escitalopram in treatment of disability and impairment in social, professional and family life in patients with MDD.

Methods

This prospective clinical study included 110 patients with MDD diagnosed by ICD-10 criteria for MDD, who are randomly divided into control (40 patients) and experimental group (70 patients). Antidepressants were tested, for 6 months in hospital and outpatients conditions, according to specially designed protocol, which included Hamilton Depression Rating Scale (HAMD) and Sheehan Disability Scale (SDS). Control group was treated with mianserine (30-90 mg/24h) and experimental group was treated with escitalopram (10-20 mg/24h).

Results

Escitalopram therapy influenced on HAMD score with high statistical significance vs. Mianserine, p=0.000. Escitalopram therapy improves all SDS scores after 6 months in comparison to Mianserine therapy with high statistical significance in Social life p=0.000, Family life/home responsibilities p=0.000, Days lost p=0.036 and Days unproductive p=0.003. Percentage of adverse effects is significantly lower in Escitalopram (10.76%) than in Mianserine (26.67%) group.

Conclusion

Escitalopram has significantly better efficacy in treatment of MDD and disability and impairment in MDD patients comparing to Mianserine, with significantly lower adverse effects rate.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E1444
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.